FDA Approves Three-Times Weekly Dose of Glatopa®

Sandoz, a Novartis division, announced today that the United States Food and Drug Administration (FDA) approved Glatopa® (glatiramer acetate injection) at a three-times weekly 40-mg dose. This generic version of Copaxone®, a disease-modifying therapy (DMT) approved for the treatment of relapsing forms of multiple sclerosis (MS), was initially approved at a 20-mg daily dose. Both […]

Read News Article

Bloomberg Senior Executive Editor Among Honorees at National Annual Benefit

John McCorry, Senior Executive Editor for the Americas at Bloomberg News; Dorothea Pfohl, Founding Member of IOMSN; and the Knights of Columbus Santa Maria Council #1443 will be recognized by MSAA The Multiple Sclerosis Association of America (MSAA) is proud to announce their distinguished honorees for the 2018 Improving Lives Benefit scheduled for Thursday, March […]

Read News Article

FDA Grants Gilenya® Breakthrough Therapy Designation for Pediatric MS

On December 18, 2017, Novartis announced that Gilenya® (fingolimod) was granted breakthrough therapy designation by the United States Food and Drug Administration (FDA) for the treatment of children and adolescents ages 10 years or older with relapsing multiple sclerosis (MS). Known as “pediatric MS,” nearly all (98 percent) of those diagnosed experience the relapsing form […]

Read News Article

Highlights from the 2017 Joint ECTRIMS-ACTRIMS Meeting

MSParis2017 was this year’s joint meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS). Each year, ECTRIMS hosts the world’s largest annual international conference devoted to basic and clinical research in multiple sclerosis, and every three years, ECTRIMS and […]

Read News Article

New Publications to Manage Multiple Sclerosis from MSAA

Free Publications Providing Extensive Information Now Available, Including the MS Relapse Toolkit and Understanding Progression in MS The Multiple Sclerosis Association of America (MSAA) has produced two new, free publications, which provide extensive information to the multiple sclerosis (MS) community on MS relapses, as well as progression in MS. The MS Relapse Toolkit is a […]

Read News Article

MSAA Expands MRI Assistance and Helpline Hours

To help meet the escalating demand for MRI assistance, MSAA is pleased to announce new program changes to the MRI Access Fund, which will increase our ability to serve more clients than ever before. Qualified clients can now receive two MRI scans (brain and c-spine) per application as well as reimbursement support for previous MRI […]

Read News Article

FDA Approves Two Doses of Generic Copaxone for MS

On October 4, 2017, Mylan announced that two doses of their generic version of Copaxone® (glatiramer acetate) had been approved by the United States Food and Drug Administration (FDA) for relapsing forms of multiple sclerosis (MS). These two separate treatments include 40 mgs taken three-times weekly and 20 mgs taken once daily, both of which […]

Read News Article

MSAA’s Mobile Phone App, My MS Manager™, Named One of the Best MS Apps of 2017 by Healthline

The Multiple Sclerosis Association of America (MSAA) is proud to announce that our free mobile phone app, My MS Manager™, has been named one of Healthline’s Best Multiple Sclerosis Apps for the fifth consecutive year! Every year, Healthline selects the top apps based on their quality, user reviews, and overall reliability as a source of […]

Read News Article

MSAA’s Magazine, The Motivator, Wins 2017 National Health Information Award

The Multiple Sclerosis Association of America (MSAA) is pleased to announce that we have received an award from the 24th Annual National Health Information Awards! Each year, the National Health Information Awards honors the nation’s best consumer health materials and programs. MSAA received a Merit Award in the Magazine category for The Motivator Summer/Fall 2016 […]

Read News Article

Highlights from the AAN and CMSC 2017 Annual Meetings

During the past few decades, advancements made in multiple sclerosis (MS) research have revolutionized the field. Thus far in 2017, the brisk pace has continued. The American Academy of Neurology (AAN) meeting in April 2017 in Boston, Massachusetts and the Consortium of MS Centers Conference (CMSC) in May 2017 in New Orleans, Louisiana were both […]

Read News Article